Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$5.07 -1.9%	$5.27	$3.55 ▼ $11.16	$390.46M	0.91	2.87 million shs	1.02 million shs
GNLX Genelux	$2.88 -7.4%	$3.36	$1.60 ▼ $5.89	$99.66M	-0.36	209,668 shs	95,457 shs
MREO Mereo BioPharma Group	$2.50 -1.6%	$2.36	$1.58 ▼ $5.02	$397.50M	0.71	1.10 million shs	2.33 million shs
ZVRA Zevra Therapeutics	$7.20 -0.6%	$7.53	$4.20 ▼ $9.76	$393.69M	1.94	610,289 shs	381,265 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+4.05%	+13.50%	-12.22%	-25.93%	-26.98%
GNLX Genelux	+7.24%	+18.25%	-8.53%	-21.46%	-9.86%
MREO Mereo BioPharma Group	-0.78%	+10.43%	+8.09%	-12.71%	-8.63%
ZVRA Zevra Therapeutics	-0.14%	+1.26%	-11.17%	-9.95%	+58.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	2.5108 of 5 stars	3.4	2.0	2.0	3.3	0.6
GNLX Genelux	0.8756 of 5 stars	3.6	0.0	1.1	0.0	0.0
MREO Mereo BioPharma Group	1.851 of 5 stars	3.6	2.0	2.1	1.7	0.0
ZVRA Zevra Therapeutics	2.606 of 5 stars	4.6	0.0	2.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.89	Moderate Buy	$20.83	310.91% Upside
GNLX Genelux	3.20	Buy	$18.25	533.68% Upside
MREO Mereo BioPharma Group	3.25	Buy	$7.71	208.57% Upside
ZVRA Zevra Therapeutics	3.11	Buy	$22.29	209.52% Upside

Current Analyst Ratings Breakdown

Latest GNLX, ZVRA, MREO, and ALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
4/3/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
3/31/2025	GNLX Genelux	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/27/2025	MREO Mereo BioPharma Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00
3/26/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/25/2025	GNLX Genelux	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/18/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
3/18/2025	MREO Mereo BioPharma Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$7.00 ➝ $7.00
3/14/2025	ALT Altimmune	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
3/13/2025	ZVRA Zevra Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00
3/13/2025	ZVRA Zevra Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00

(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$20K	19,523.05	N/A	N/A	$2.75 per share	1.84
GNLX Genelux	$8K	12,457.44	N/A	N/A	$0.73 per share	3.95
MREO Mereo BioPharma Group	$1M	397.50	N/A	N/A	$0.36 per share	6.94
ZVRA Zevra Therapeutics	$23.61M	16.67	N/A	N/A	$1.71 per share	4.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$88.45M	-$1.34	N/A	N/A	N/A	-199,076.92%	-55.81%	-50.60%	5/8/2025 (Estimated)
GNLX Genelux	-$28.30M	-$0.96	N/A	N/A	N/A	N/A	-105.05%	-80.16%	5/8/2025 (Estimated)
MREO Mereo BioPharma Group	-$29.47M	-$0.06	N/A	N/A	N/A	N/A	N/A	N/A	5/21/2025 (Estimated)
ZVRA Zevra Therapeutics	-$46.05M	-$2.24	N/A	36.00	N/A	-342.63%	-159.54%	-51.50%	5/5/2025 (Estimated)

Latest GNLX, ZVRA, MREO, and ALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	MREO Mereo BioPharma Group	-$0.01	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	ZVRA Zevra Therapeutics	-$0.21	N/A	N/A	N/A	$16.96 million	N/A
5/8/2025	Q1 2025	ALT Altimmune	-$0.36	N/A	N/A	N/A	$0.00 million	N/A
5/8/2025	N/A	GNLX Genelux	-$0.24	N/A	N/A	N/A	N/A	N/A
3/28/2025	Q4 2024	GNLX Genelux	-$0.17	-$0.26	-$0.09	-$0.26	N/A	N/A
3/26/2025	Q4 2024	MREO Mereo BioPharma Group	$0.02	-$0.01	-$0.03	-$0.01	$72.50 million	N/A
3/11/2025	Q4 2024	ZVRA Zevra Therapeutics	-$0.39	-$0.67	-$0.28	-$0.67	$8.93 million	$12.00 million
2/27/2025	Q4 2024	ALT Altimmune	-$0.34	-$0.33	+$0.01	-$0.33	$0.00 million	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	16.87	16.87
GNLX Genelux	N/A	6.47	6.47
MREO Mereo BioPharma Group	N/A	6.10	6.10
ZVRA Zevra Therapeutics	0.84	2.88	2.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
GNLX Genelux	37.33%
MREO Mereo BioPharma Group	62.83%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
GNLX Genelux	9.30%
MREO Mereo BioPharma Group	5.50%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	77.01 million	68.21 million	Optionable
GNLX Genelux	10	34.60 million	31.33 million	Not Optionable
MREO Mereo BioPharma Group	40	159.00 million	148.74 million	Optionable
ZVRA Zevra Therapeutics	20	54.68 million	52.10 million	Optionable

GNLX, ZVRA, MREO, and ALT Headlines

Recent News About These Companies

Diadema Partners LP Makes New Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

April 24 at 7:17 AM | marketbeat.com

Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders

April 21, 2025 | finance.yahoo.com

Zevra Therapeutics urges stockholders to vote for director nominees

April 21, 2025 | markets.businessinsider.com

Zevra Therapeutics Urges Stockholders to Vote "FOR" Qualified Directors Amid Proxy Contest Concerns

April 21, 2025 | quiverquant.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Position Boosted by Altium Capital Management LLC

April 19, 2025 | marketbeat.com

Zevra Therapeutics announces publication on arimoclomol

April 18, 2025 | markets.businessinsider.com

Zevra Therapeutics Publishes Study on Arimoclomol's Mechanism of Action in Niemann-Pick Type C Disease

April 17, 2025 | quiverquant.com

Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

April 17, 2025 | globenewswire.com

Vanguard Group Inc. Grows Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

April 17, 2025 | marketbeat.com

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

April 7, 2025 | globenewswire.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of "Buy" by Brokerages

April 7, 2025 | marketbeat.com

Zevra Therapeutics: Mixed Feelings On Miplyffa Approval

April 3, 2025 | seekingalpha.com

Zevra Therapeutics Files Preliminary Proxy

March 31, 2025 | globenewswire.com

AIGH Capital Management LLC Invests $6.58 Million in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

March 31, 2025 | marketbeat.com

Zevra Therapeutics management to meet with Cantor Fitzgerald

March 26, 2025 | markets.businessinsider.com

Bank of New York Mellon Corp Sells 37,365 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

March 26, 2025 | marketbeat.com

Zevra Therapeutics Independent Director Acquires 33% More Stock

March 23, 2025 | finance.yahoo.com

Insider Buying: Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Director Buys 10,000 Shares of Stock

March 22, 2025 | insidertrades.com

Zevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

March 14, 2025 | finance.yahoo.com

Zevra Therapeutics’ Earnings Call Highlights Success and Growth

March 12, 2025 | tipranks.com

Zevra Therapeutics: Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

March 12, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX, ZVRA, MREO, and ALT Company Descriptions

Altimmune NASDAQ:ALT

$5.07 -0.10 (-1.93%)

Closing price 04:00 PM Eastern

Extended Trading

$5.10 +0.03 (+0.61%)

As of 07:59 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Genelux NASDAQ:GNLX

$2.88 -0.23 (-7.40%)

Closing price 04:00 PM Eastern

Extended Trading

$2.95 +0.07 (+2.43%)

As of 07:47 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Mereo BioPharma Group NASDAQ:MREO

$2.50 -0.04 (-1.57%)

Closing price 04:00 PM Eastern

Extended Trading

$2.51 +0.01 (+0.40%)

As of 05:00 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Zevra Therapeutics NASDAQ:ZVRA

$7.20 -0.04 (-0.55%)

Closing price 04:00 PM Eastern

Extended Trading

$7.20 0.00 (-0.07%)

As of 04:13 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time